Dr. Reddy’s Laboratories stopped worldwide shipments of the heartburn drug ranitidine after the FDA found it contained N-nitrosodimethylamine, which is classified as a probable human carcinogen.
The Italian Drug Agency and Germany’s drug regulator will both order a recall of all versions of Zantac with an active ingredient made in India’s Saraca Laboratories, according to Bloomberg. Canada has also asked all makers of ranitidine-containing products to stop distribution.
Last week, Sandoz, the generic arm of Novartis, stopped worldwide distribution of its generic version of Zantac.
Sanofi, the maker of the brand-name Zantac medication, has not halted distribution of any ranitidine products outside of Canada.
Read the full report here.
More articles on pharmacy:
FDA approves first oral treatment for Type 2 diabetes
FDA finalizes rules to prevent improper petitions from delaying drug approvals
Pharmacists can play key role in preventing Hepatitis A outbreak
More articles on pharmacy:
FDA approves first oral treatment for Type 2 diabetes
FDA finalizes rules to prevent improper petitions from delaying drug approvals
Pharmacists can play key role in preventing Hepatitis A outbreak
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.